ArticleBlood2014

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.

Paolo Gallipoli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.